im glad for you and every single patient that benefits from something i work on. From the public health angle of most eu countries investment into novel cancer treatments makes a lot less sense that improving prevention.
not "war on cancer" and not "we" winning. It's pharma finding ways how to profit from rare treatment successes of few rare disease types. Majority, and by majority i mean over 80%, of patients and cancer types are still treated with bogstandard chemo+radio+surgery. Individualized treatment plans using checkpoint inhibitor combinations, biotech therapies, etc are for few select individuals with A LOT of money.
how do i know? i work in precision oncology for a decade plus
and you can absolutely evaluate how smart someone is in a 2min casual conversation. You wont be able to tell how well they are in some niche topic, but %insert something about different flavors of intelligence and how they do not equate do subject matter expertise%
this really depends who you are listening to, eg compare some archetypical bigroom corporate techno performer like Charlotte deWitte vs some crate digger like Om Unit, or since we talk about techno, uhm, Tommy Fourseven
continuous bioreactors are a pain to operate due to high risk of contamination, need for precise environment control and validation protocols. They have also been known for decades and are extensively used in process development. Despite all that most things are still produced in (fed)batch mode. So yeah thats still mostly marketing talk from ginkgo people, that are well-known for this kinda shit